Comprehensive analyses of PBRM1 in multiple cancer types and its association with clinical response to immunotherapy and immune infiltrates

Abstract

Our findings suggested caution in starting immunotherapy alone in <i>PBRM1</i> mutant patients. Further studies are needed to improve treatment for <i>PBRM1</i> mutant patients.